Summit Trail Advisors’s Alkermes ALKS Stock Holding History

Summit Trail Advisors’s Portfolio ALKS Stock Details ALKS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-160	Closed	-$9K	–	463
2017 Q4	$9K	Buy	+160	New	+$8.16K	﹤0.01%	1239

Other funds holding ALKS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Summit Trail Advisors's ALKS Position: Q1 2018 in Review

Summit Trail Advisors sold out of Alkermes (ALKS) in Q1 2018, closing a stake of 160 shares — an estimated $9K sold.

Summit Trail Advisors first reported a position in ALKS in Q4 2017 and held it in 1 quarter. The position peaked at $9K in Q4 2017. 271 funds tracked by Wall St. Rank hold ALKS as of Q1 2018.

Summit Trail Advisors reported no remaining Alkermes position as of Q1 2018 after selling out during the quarter.
Summit Trail Advisors sold 160 Alkermes shares in Q1 2018, an estimated $9K.
Summit Trail Advisors first reported a position in Alkermes in Q4 2017 and held it in 1 quarter.
Summit Trail Advisors's Alkermes position peaked at $9K in Q4 2017.
271 funds tracked by Wall St. Rank held Alkermes as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.